SuperworthAEON Biopharma AEON
- Market cap
- $12M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
AEON Biopharma's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY23 | Q2 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $9.2M | $9M | $5.7M | $4.4M | $972K | $3M | $825K−86% | $1.1M−76% | $597K−39% | $1.6M−47% | $2M+147% | $2.9M+176% |
| SG&A | $3.8M | $4.9M | $4.6M | $3.3M | $3M | $2.6M | $3.1M−33% | $3.3M−2% | $1.9M−37% | $3.9M+48% | $3.9M+25% | $3M−8% |
| −$13M+3253% | −$14M+3170% | −$74.2M | $153.5M | −$4M | −$2.3M | −$462K−99% | −$4.3M | −$2.5M−38% | −$5.5M+137% | −$5.9M+1184% | −$5.9M+36% | |
| Pre-tax income | −$17.6M | −$15.4M | −$118M | $164.1M | −$6.2M | $2.1M | $9.1M | −$6.6M | −$4.5M−27% | −$37.1M | −$11.8M | −$1.2M−83% |
| $404.6K | $91.7K+440% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$17.6M | −$3.9M | −$118M | $164.1M | −$6.2M | $2.1M | $9.1M | −$6.6M | −$4.5M−27% | −$37.1M | −$11.8M | −$1.2M−83% |
| −$9.36 | −$7.92 | −$227.87 | $304.00 | −$11.24 | $3.58 | $2.28 | −$0.60 | −$0.39−97% | −$2.89 | −$0.29 | −$0.02−97% | |
| 1.9M+403% | 1.9M+403% | 517.9K | 539.8K | 549.2K | 581.1K | 4M+669% | 11.1M+1955% | 11.6M+2019% | 12.9M+2113% | 40.6M+919% | 50.5M+356% |
Net income: Q3 FY22 and Q1 FY23: not printed by the filing, worked out from its own lines.
EPS, diluted: 4 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY21 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest AEON Biopharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AEONAEON Biopharma | $12M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on AEON Biopharma
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .